Find investors
← Back to all investors
John Maldonado
ResearchedAngel Investors

John Maldonado

Managing Partner

Angel InvestorsSeed Round
Pitch John

Get their honest, personalized take on your startup.

Sign in to pitch John →

At a glance

Full Name
John Maldonado
Title
Managing Partner & Co-Head of North America
Firm
Advent International
Firm Type
Global private equity (buyout & growth) — *not an angel investor; the "Angel Investors / Seed Round" label in the stub is incorrect*
Investment Stage
Buyouts, growth equity, and control investments in established companies (large-cap private equity)
Check Size
Large-cap equity checks — Advent typically deploys hundreds of millions to over a billion dollars per deal (specific per-deal figures not publicly disclosed)
Target Company Profile
Established, market-leading companies with strong management teams; control buyouts and platform investments
Sector Focus
Healthcare, and Business & Financial Services
Geographic Focus
North America (United States), within Advent's global platform
Location
Boston, Massachusetts

Background

John Maldonado is a Managing Partner at Advent International and serves as Co-Head of North America, based in the firm's Boston headquarters. He joined Advent in 2006 and has spent roughly two decades focused on control buyouts in the healthcare and business & financial services sectors. Over his career he has advised on 25 investments, 22 of them at Advent, and he also serves on Advent's leadership committees (reported as Co-Chair of the firm's Executive Committee).

Before Advent, Maldonado built a career across strategy consulting and private equity. He began as a consultant at The Parthenon Group, a leading strategy consulting firm, and then worked in private equity at Bain Capital and Parthenon Capital before moving to Advent.

He was educated at Dartmouth College, where he earned a BA, summa cum laude, and at Harvard Business School, where he received an MBA with high distinction as a Baker Scholar (a distinction reserved for the top of the graduating class).

In his current role he sits on the boards of several Advent portfolio companies and healthcare-focused entities, and he is a public voice for the firm — for example, appearing on CNBC's "Closing Bell" in early 2025 to discuss Advent's outlook on M&A, IPO markets, interest rates, and AI-driven opportunities.

Investment Thesis & Focus

  • Invests through control buyouts and growth investments in established, market-leading businesses — this is large-cap private equity, not seed/angel investing.
  • Sector concentration: healthcare (services, pharma/biopharma, healthcare technology) and business & financial services.
  • Emphasizes partnering closely with strong management teams — he has stated that "great deals are born from great talent."
  • Credits Advent's privately-owned partnership structure for allowing the firm to focus on building exceptional, durable businesses alongside management rather than chasing short-term growth metrics.
  • Geographic remit centers on North America within Advent's global sector-focused model.

Notable Investments

  • Waystar (formerly Iodine Software) — healthcare payments/revenue-cycle technology; Advent-backed, later a public company. Maldonado held a board seat at Iodine Software.
  • Genoa Healthcare — pharmacy services provider serving behavioral health populations.
  • Syneos Health — biopharmaceutical outsourcing / clinical and commercial services organization.
  • Simtra BioPharma Solutions — sterile contract development and manufacturing (CDMO) carve-out.
  • Bharat Serums and Vaccines (BSV) — Indian biopharmaceutical company (women's health and critical care).
  • Cohance Lifesciences (formerly Suven) — pharma CDMO platform in India.
  • Apollo 24/7 / Apollo-related healthcare — digital healthcare investment.
  • Felix — Advent-listed investment among his healthcare deals.
  • AccentCare — home health and hospice services provider; Maldonado has served as a director (since ~2019).
  • RxBenefits — pharmacy benefits optimization company; Maldonado has served as a director (since ~2021).

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.